BMS Opdivo To Make Splash in Blood Cancer
New data show that Bristol-Myers Squibb Co.'s Opdivo (nivolumab) has promise in treating Hodgkin's lymphoma reinforcing the notion that checkpoint inhibitors have potential in a broad range of cancers.
You may also be interested in...
Combo of Seattle Genetics' antibody-drug conjugate Adcetris and BMS's PD-1 inhibitor Opdivo demonstrates 90% objective response rate and 62% complete response rate in relapsed Hodgkin lymphoma, and further investigation of the pairing seems on the cards.
Merck claims to have the broadest clinical development program for an anti-PD-1/L1 drug, with more than 270 trials under way testing Keytruda in 30 tumor types and 100 combinations.
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an expanded indication for Merck & Co.’s PD-1 antagonist Keytruda (pembrolizumab).